(Circulation. 1997;96:856-863.)
© 1997 American Heart Association, Inc.
Articles |
Effect of the Calcium Antagonist Felodipine as Supplementary Vasodilator Therapy in Patients With Chronic Heart Failure Treated With Enalapril
V-HeFT III
From the Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, and the Veterans Affairs Medical Center, Minneapolis, Minn.
Correspondence to Jay N. Cohn, MD, Cardiovascular Division, University of Minnesota Medical School, Box 508 UMHC, 420 Delaware St SE, Minneapolis, MN 55455.
Background Despite therapy with diuretics, ACE inhibitors and digoxin morbidity and mortality in heart failure remain high and might respond favorably to an additional vasodilator.
Methods and Results Male patients (n=450) with chronic heart failure (cardiac dysfunction and impaired exercise performance) on optimal current therapy (97% enalapril, 89% diuretics) were randomly assigned to double-blind treatment with felodipine extended release (5 mg BID) or placebo for 3 to 39 months (average, 18 months). Felodipine significantly reduced blood pressure and, at 3 months, increased ejection fraction (2.1% versus -0.1% units in the placebo group, P=.001) and reduced plasma atrial natriuretic peptide levels (-2.9 versus 26.9 pg/mL in the placebo group, P=.01) but did not improve exercise tolerance, quality of life, or the need for hospitalization. During long-term follow-up, the favorable effects on ejection fraction and atrial peptide did not persist, but felodipine prevented worsening exercise tolerance and quality of life. In the felodipine and placebo groups, mortality (13.8% versus 12.8%, respectively) and hospitalization (43% versus 42%) rates were similar, and a higher incidence of peripheral edema was the only apparent side effect of felodipine therapy.
Conclusions Felodipine exerts a well-tolerated additional sustained vasodilator effect in patients with heart failure treated with enalapril, but the only possible long-term benefit was a trend for better exercise tolerance and less depression of quality of life in the second year of treatment. The drug appears to be safe but not clearly efficacious in patients with heart failure.
Key Words: heart failure • calcium channels • norepinephrine • atrial natriuretic factor • morbidity
This article has been cited by other articles:
 |
|
 |
|
  S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
 |
|
 2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Dart, J. E. Otterstad, B.-A. Kirwan, J. D. Parker, S. de Brouwer, P. A. Poole-Wilson, and J. Lubsen Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study Eur J Echocardiogr, August 1, 2007; 8(4): 275 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Hypertension, August 1, 2007; 50(2): e28 - e55. [Full Text] [PDF]
|
|
|
|
|
|
C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation, May 29, 2007; 115(21): 2761 - 2788. [Full Text] [PDF]
|
|
|
|
|
|
A. L. Taylor, S. Ziesche, C. W. Yancy, P. Carson, K. Ferdinand, M. Taylor, K. Adams, A. Y. Olukotun, E. Ofili, S. W. Tam, et al. Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial Circulation, April 3, 2007; 115(13): 1747 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Aronow Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2005; 60(12): 1597 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, K. Swedberg, Writing Committee:, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, L. Tavazzi, O. A. Smiseth, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur. Heart J., June 1, 2005; 26(11): 1115 - 1140. [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Moran, R. S. Cooper, T. P. Fitzgibbons, A. Y. Chow, E. Y. Bellin, A. B. Eisenberger, A. L. Taylor, J. Cohn, and M. Worcel Isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med., March 10, 2005; 352(10): 1041 - 1043. [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Amabile and A. P. Spencer Keeping Your Patient With Heart Failure Safe: A Review of Potentially Dangerous Medications Arch Intern Med, April 12, 2004; 164(7): 709 - 720. [Full Text] [PDF]
|
|
|
|
 |
|
 D B McKenzie and A J Cowley Drug therapy in chronic heart failure Postgrad. Med. J., November 1, 2003; 79(937): 634 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Houser and K. B. Margulies Is Depressed Myocyte Contractility Centrally Involved in Heart Failure? Circ. Res., March 7, 2003; 92(4): 350 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Latini, S. Masson, I. Anand, D. Judd, A. P. Maggioni, Y.-T. Chiang, M. Bevilacqua, M. Salio, P. Cardano, P. H.J.M. Dunselman, et al. Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) Circulation, November 5, 2002; 106(19): 2454 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hulsmann, R. Berger, B. Sturm, A. Bojic, W. Woloszczuk, J. Bergler-Klein, and R. Pacher Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure Eur. Heart J., June 1, 2002; 23(11): 886 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Alpert, L. A. Mulieri, and D. Warshaw The failing human heart Cardiovasc Res, April 1, 2002; 54(1): 1 - 10. [Full Text] [PDF]
|
|
|
|
|
|
G. C. Fonarow Quality Indicators for the Management of Heart Failure in Vulnerable Elders Ann Intern Med, October 16, 2001; 135(8_Part_2): 694 - 702. [Full Text] [PDF]
|
|
|
|
|
|
Task Force for the Diagnosis and Treatment of Chro, W. J. Remme, and K. Swedberg Guidelines for the diagnosis and treatment of chronic heart failure Eur. Heart J., September 1, 2001; 22(17): 1527 - 1560. [PDF]
|
|
|
|
|
|
J. R. Kizer and S. E. Kimmel Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards Arch Intern Med, May 14, 2001; 161(9): 1145 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gomberg-Maitland, D. A. Baran, and V. Fuster Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist Arch Intern Med, February 12, 2001; 161(3): 342 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Opie First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1967 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Cohn, R. Ferrari, N. Sharpe, and on Behalf of an International Forum on Cardiac Rem Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling J. Am. Coll. Cardiol., March 1, 2000; 35(3): 569 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schunkert The importance of early intervention in CHF -- signs and symptom relief Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1_suppl): 17 - 23. [Abstract] [PDF]
|
|
|
|
 |
|
 R. D. Feldman, N. Campbell, P. Larochelle, P. Bolli, E. D. Burgess, S. G. Carruthers, J. S. Floras, R. B. Haynes, G. Honos, F. H.H. Leenen, et al. 1999 Canadian recommendations for the management of hypertension Can. Med. Assoc. J., December 14, 1999; 161(90120): S1 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Abernethy and J. B. Schwartz Calcium-Antagonist Drugs N. Engl. J. Med., November 4, 1999; 341(19): 1447 - 1457. [Full Text] [PDF]
|
|
|
|
|
|
J. Feenstra, D. E. Grobbee, W. J. Remme, and B. H. C. Stricker Drug-induced heart failure J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1152 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Grassi, D. Spaziani, G. Seravalle, G. Bertinieri, R. Dell'Oro, C. Cuspidi, and G. Mancia Effects of Amlodipine on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure Hypertension, February 1, 1999; 33(2): 671 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Follath, J. G. F. Cleland, W. Klein, and R. Murphy Etiology and response to drug treatment in heart failure J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1167 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade and R. O. Bonow Chronic Heart Failure in the United States : A Manifestation of Coronary Artery Disease Circulation, January 27, 1998; 97(3): 282 - 289. [Full Text] [PDF]
|
|
|
|
 |
|
 Felodipine Fails in CHF Journal Watch Cardiology, August 18, 1997; 1997(818): 9 - 9. [Full Text]
|
|